GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen
DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with
pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis
of HCC based on pathology report.